When Will There Ever Be a Cure for Hepatitis B?

You’ve probably seen the bumper stickers, T-shirts, and memes that declare: “The liver is evil, it must be punished.” We have been known to indulge in a little BDSM with our own meaty organ in a local dive bar or three, hoping that we don’t drink it under the table some day. While there are plenty […]

Synlogic Becomes a Synthetic Biology Stock

One downside of having to show up at 8:00 AM every morning to kick off your cushy finance job is all the new language you need to start using. We’re talking about corporate neologisms that try and soften the blow of certain “touchy” terms. Take for example the newly coined term “RIF” which stands for […]

Benitec: A Small RNAi Stock with Big Hopes

In a previous article, we provided a list of 7 publicly traded companies involved in the RNAi Therapeutics space. With the recent IPO of Mirna Therapeutics (NASDAQ:MIRN) and the Benitec listing ADR listing (NASDAQ:BNTC), we can now rebalance our original RNAi therapeutics portfolio for a total of 9 stocks as seen below: When creating this portfolio, […]

Why Moderna Therapeutics Won’t IPO Anytime Soon

We recently wrote an article about 7 publicly traded stocks that are involved in the exciting field of RNA therapeutics or what is often referred to as RNA interference (RNAi). In that article, we noted that not all “RNA therapeutics” companies are created equal and there are actually quite a few categorizations of RNA therapeutics. mRNA is […]

7 RNA Therapeutics Companies to Invest In

RNA therapeutics uses a technology called RNA interference (RNAi) which has rapidly advanced over the past few years and generated a great deal of interest from biotech investors. RNAi is a gene-silencing technology that turns on and off the genes that regulate proteins in people’s cells. Drugs being developed based on this technology have recently advanced, mostly due to improved […]

A microRNA IPO from Microlin Bio

RNA Interference (RNAi) is a breakthrough in understanding how genes are turned on and off in cells and is widely considered to be one of the most promising and rapidly advancing frontiers in biology and drug development today. The importance of its discovery was recognized by the award of the 2006 Nobel Prize for Physiology or Medicine. […]

RNAi Developer Dicerna Pharmaceuticals to IPO

RNA Interference (RNAi) is a new approach in the development of specific targeted therapies against both rare diseases and cancer. Historically, the pharmaceutical industry has developed two fundamental classes of drugs that can address well-defined targets: small molecules and antibodies. Both of these drug classes have been very successful but are limited in the nature of the […]